+検索条件
-Structure paper
タイトル | Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. |
---|---|
ジャーナル・号・ページ | Nat Biotechnol, Vol. 40, Issue 8, Page 1270-1275, Year 2022 |
掲載日 | 2022年3月3日 |
![]() | Andrea R Shiakolas / Kevin J Kramer / Nicole V Johnson / Steven C Wall / Naveenchandra Suryadevara / Daniel Wrapp / Sivakumar Periasamy / Kelsey A Pilewski / Nagarajan Raju / Rachel Nargi / Rachel E Sutton / Lauren M Walker / Ian Setliff / James E Crowe / Alexander Bukreyev / Robert H Carnahan / Jason S McLellan / Ivelin S Georgiev / ![]() |
PubMed 要旨 | Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development ...Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development was generally inefficient, with lead generation often requiring the production and testing of numerous antibody candidates. Here, we report that the integration of target-ligand blocking with a previously described B cell receptor-sequencing approach (linking B cell receptor to antigen specificity through sequencing (LIBRA-seq)) enables the rapid and efficient identification of multiple neutralizing mAbs that prevent the binding of SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme 2 (ACE2). The combination of target-ligand blocking and high-throughput antibody sequencing promises to increase the throughput of programs aimed at discovering new neutralizing antibodies. |
![]() | ![]() ![]() ![]() |
手法 | EM (単粒子) |
解像度 | 8.64 Å |
構造データ | ![]() EMDB-26064: |
由来 |
|